Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H28F2O5 |
Molecular Weight | 410.4515 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C
InChI
InChIKey=WXURHACBFYSXBI-GQKYHHCASA-N
InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
Molecular Formula | C22H28F2O5 |
Molecular Weight | 410.4515 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00663Curator's Comment: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00663
Curator's Comment: Description was created based on several sources, including
Flumethasone or flumetasone is a corticosteroid and is an agonist of a glucocorticoid receptor with anti-inflammatory, antipruritic and vasoconstrictive properties. Flumethasone is often formulated as the pivalic acid ester, flumetasone pivalate. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flumethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin. Flumethasone is used for the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin condition.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00663 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LOCORTEN Approved UseThis medication is used in corticosteroid-responsive dermatoses. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30080272/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUMETHASONE serum | Equus caballus population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30080272/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUMETHASONE serum | Equus caballus population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30080272/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUMETHASONE serum | Equus caballus population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Determination of flumethasone in calf urine and serum by liquid chromatography-tandem mass spectrometry. | 2001 May 5 |
|
A high-performance liquid chromatography/tandem mass spectrometric screening method for eight synthetic corticosteroids in bovine feces and the simultaneous differentiation between dexamethasone and betamethasone. | 2002 |
|
Immunochemical screening and liquid chromatographic-tandem mass spectrometric confirmation of drug residues in edible tissues of calves injected with a therapeutic dose of the synthetic glucocorticoids dexamethasone and flumethasone. | 2003 Jan 1 |
|
Effect of steroidal and non-steroidal anti-inflammatory drugs in combination with long-acting oxytetracycline on non-specific immunity of calves suffering from enzootic bronchopneumonia. | 2003 Oct 8 |
|
Otic drops used to clear a blocked grommet: an in vitro prospective randomized controlled study with blinded assessment. | 2004 Dec |
|
Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. | 2004 Sep |
|
Regression of subcorneal pustular dermatosis type of IgA pemphigus lesions with azithromycin. | 2005 Aug |
|
Effect of steroidal and non-steroidal anti-inflammatory drugs on inflammatory markers in calves with experimentally-induced bronchopneumonia. | 2005 Jul-Aug |
|
A chromatography method for the screening and confirmatory detection of dexamethasone. | 2006 Dec |
|
Medical treatment of vulvar squamous cell hyperplasia. | 2006 Dec |
|
Rapid multi-residue method for the quantitative determination and confirmation of glucocorticosteroids in bovine milk using liquid chromatography-electrospray ionization-tandem mass spectrometry. | 2007 Apr 4 |
|
Flexor carpi ulnaris tendonopathy in a Weimaraner. | 2007 Oct |
|
A liquid chromatography method using a monolithic column for the determination of corticoids in animal feed and animal feeding water. | 2008 Aug |
|
Optimization of solid phase extraction clean up and validation of quantitative determination of corticosteroids in urine by liquid chromatography-tandem mass spectrometry. | 2008 Jun 9 |
|
Validation of a solid-phase extraction and ultra-performance liquid chromatographic tandem mass spectrometric method for the detection of 16 glucocorticoids in pig tissues. | 2009 Mar-Apr |
|
Determination of anabolic steroids in muscle tissue by liquid chromatography-tandem mass spectrometry. | 2009 Nov 13 |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
Quantitative determination of corticosteroids in bovine milk using mixed-mode polymeric strong cation exchange solid-phase extraction and liquid chromatography-tandem mass spectrometry. | 2010 Dec 1 |
|
Screening and quantitative confirmatory method for the analysis of glucocorticoids in bovine milk using liquid chromatography-tandem mass spectrometry. | 2010 Sep-Oct |
Patents
Sample Use Guides
Apply a sparingly thin layer of 0.02% cream, ointment or lotion over affected areas bid-tid for 7-10 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2379953
Flumethasone inhibited PAF-induced N-PMN (neutrophils from newborn calves) aggregation at the highest dose - 122 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:38:02 GMT 2023
by
admin
on
Fri Dec 15 16:38:02 GMT 2023
|
Record UNII |
LR3CD8SX89
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
D07BB01
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-VATC |
QD07CB05
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-VATC |
QD07BB01
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-VATC |
QD07XB01
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
CFR |
21 CFR 522.960A
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
CFR |
21 CFR 520.960
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-ATC |
D07AB03
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-VATC |
QS02CA02
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-ATC |
D07CB05
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
CFR |
21 CFR 522.960
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
CFR |
21 CFR 522.960C
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-ATC |
D07XB01
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-VATC |
QD07AB03
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-ATC |
S02CA02
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
CFR |
21 CFR 524.960
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
||
|
WHO-VATC |
QH02AB90
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
218-370-9
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
34764
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
4548
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
DTXSID2045365
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
54702
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
4458
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | RxNorm | ||
|
31623
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
100000080687
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
2135-17-3
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
LR3CD8SX89
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
FLUMETASONE
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
SUB07698MIG
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201392
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
m5439
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
16490
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
LR3CD8SX89
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
DB00663
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
C65717
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
1355
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY | |||
|
D005443
Created by
admin on Fri Dec 15 16:38:02 GMT 2023 , Edited by admin on Fri Dec 15 16:38:02 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DEGRADENT -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |